Trial reportNEJM evidence2024
Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention.
Trial report in NEJM evidence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03546413 (Follow up of Learning Early About Peanut Allergy), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Follow up of Learning Early About Peanut Allergy (LEAP) Participants and Their Families: LEAP Trio (ITN070AD)
Who cites it
16 citing papers in PubMed.
- Pediatric Clinician Adherence to Peanut Allergy Prevention Guidelines: A Randomized Trial.Pediatrics · 2025Trial
- Diet-Microbiome-Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications.Allergy · 2026Review
- Immunization with Virus-Like Particles Displaying Ara h 2‑Derived Peptides to Mitigate Peanut Allergy.ACS nano medicine · 2026Article
- Review
- Eosinophil-epithelial interactions mediate protective intestinal remodeling during food allergy.bioRxiv : the preprint server for biology · 2026Article
- Early Peanut Introduction for Allergy Prevention: Evidence and Practical Implementation in Pediatric Practice.Cureus · 2026Review
- Genetic Determinants of Peanut-Specific IgG4 Levels in the Context of Sustained Oral Peanut Exposure in the LEAP Study.Immunology · 2026Article
- Early Allergen Introduction in Delaware: A Model to Address Healthcare Disparities and Population Healthcare Costs.Cureus · 2026Review
- Decision Support Tools Strengthen Early Peanut Introduction Practices and Streamline Data Automation.Cureus · 2026Article
- Oral antigen exposure under costimulation blockade induces Treg cells to establish immune tolerance.The Journal of experimental medicine · 2026Article
- Guidelines for Early Food Introduction and Patterns of Food Allergy.Pediatrics · 2025Article
- Novel approaches to prevent or cure allergic diseases.Current opinion in immunology · 2025Review
- Epitope-Specific Antibodies in Allergic Disease and Clinical Tolerance.Immunological reviews · 2025Review
- Macronutrients, Micronutrients, and Malnutrition: Effects of Nutrition on Immune Function in Infants and Young Children.Nutrients · 2025Review
- Zéro allergie research clinic: a clinical and research initiative in oral immunotherapy for managing IgE-mediated food allergy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Oral tolerance to dietary antigens and Foxp3Immunological reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundA randomized trial demonstrated consumption of peanut from infancy to age 5 years prevented the development of peanut allergy. An extension of that trial demonstrated the effect persisted after 1 year of peanut avoidance. This follow-up trial examined the durability of peanut tolerance at age 144 months after years of ad libitum peanut consumption.
methodsParticipants from a randomized peanut consumption trial were assessed for peanut allergy following an extended period of eating or avoiding peanuts as desired. The primary end point was the rate of peanut allergy at age 144 months.
resultsWe enrolled 508 of the original 640 participants (79.4%); 497 had complete primary end point data. At age 144 months, peanut allergy remained significantly more prevalent in participants in the original peanut avoidance group than in the original peanut consumption group (15.4% [38 of 246 participants] vs. 4.4% [11 of 251 participants]; P<0.001). Participants in both groups reported avoiding peanuts for prolonged periods of time between 72 and 144 months. Participants at 144 months in the peanut consumption group had levels of Ara h2-specific immunoglobulin E (a peanut allergen associated with anaphylaxis) of 0.03 ± 3.42 kU/l and levels of peanut-specific immunoglobulin G4 of 535.5 ± 4.98 μg/l, whereas participants in the peanut avoidance group had levels of Ara h2-specific immunoglobulin E of 0.06 ± 11.21 kU/l and levels of peanut-specific immunoglobulin G4 of 209.3 ± 3.84 μg/l. Adverse events were uncommon, and the majority were related to the food challenge.
conclusionsPeanut consumption, starting in infancy and continuing to age 5 years, provided lasting tolerance to peanut into adolescence irrespective of subsequent peanut consumption, demonstrating that long-term prevention and tolerance can be achieved in food allergy. (Funded by the National Institute of Allergy and Infectious Diseases and others; ITN070AD, ClinicalTrials.gov number, NCT03546413.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.